Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.

The top 5 OncLive TV videos of the week.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.